Lovenox
Lovenox is the brand name for enoxaparin, a low-molecular-weight heparin (LMWH) used as an anticoagulant. It helps prevent and treat thromboses—blood clots that can form in the legs (deep vein thrombosis, or DVT) or travel to the lungs (pulmonary embolism). It is also used to reduce clot risk in patients undergoing certain surgeries or with certain cardiac conditions like unstable angina.
Enoxaparin works by binding to antithrombin III, enhancing its ability to inactivate coagulation factors, most notably factor Xa. This action prevents the formation and extension of blood clots. Compared to unfractionated heparin, Lovenox has more predictable pharmacokinetics, which often allows for subcutaneous dosing without the need for continuous intravenous infusion or intensive laboratory monitoring of the aPTT (activated partial thromboplastin time).
Dosing regimens depend on whether Lovenox is used prophylactically (to prevent clots) or therapeutically (to treat existing clots). Often administered by subcutaneous injection in the abdomen, Lovenox may be given once or twice daily. Patients may be taught how to self-inject, making it more convenient for outpatient treatment.
Possible side effects include bleeding, bruising at the injection site, and, in rare cases, heparin-induced thrombocytopenia (HIT)—a severe drop in platelet count that can paradoxically increase clotting risk. Monitoring platelet counts and being aware of signs like unexplained swelling or bleeding are vital for safety. Patients are also encouraged to rotate injection sites to reduce local irritation or bruising.
Lovenox is often combined with other therapies, including oral anticoagulants such as warfarin or direct oral anticoagulants (DOACs), depending on the clinical situation. Close coordination with healthcare providers is necessary to ensure proper overlap and transition if switching medications. By effectively reducing clot formation with a relatively predictable dosing profile, Lovenox continues to be a key agent in modern thromboprophylaxis and anticoagulant therapy.
NOTE: The above information is for marketing purposes only and is not to be construed as medical advice. Seek advice for medications from a qualified physician.
Enoxaparin works by binding to antithrombin III, enhancing its ability to inactivate coagulation factors, most notably factor Xa. This action prevents the formation and extension of blood clots. Compared to unfractionated heparin, Lovenox has more predictable pharmacokinetics, which often allows for subcutaneous dosing without the need for continuous intravenous infusion or intensive laboratory monitoring of the aPTT (activated partial thromboplastin time).
Dosing regimens depend on whether Lovenox is used prophylactically (to prevent clots) or therapeutically (to treat existing clots). Often administered by subcutaneous injection in the abdomen, Lovenox may be given once or twice daily. Patients may be taught how to self-inject, making it more convenient for outpatient treatment.
Possible side effects include bleeding, bruising at the injection site, and, in rare cases, heparin-induced thrombocytopenia (HIT)—a severe drop in platelet count that can paradoxically increase clotting risk. Monitoring platelet counts and being aware of signs like unexplained swelling or bleeding are vital for safety. Patients are also encouraged to rotate injection sites to reduce local irritation or bruising.
Lovenox is often combined with other therapies, including oral anticoagulants such as warfarin or direct oral anticoagulants (DOACs), depending on the clinical situation. Close coordination with healthcare providers is necessary to ensure proper overlap and transition if switching medications. By effectively reducing clot formation with a relatively predictable dosing profile, Lovenox continues to be a key agent in modern thromboprophylaxis and anticoagulant therapy.
NOTE: The above information is for marketing purposes only and is not to be construed as medical advice. Seek advice for medications from a qualified physician.
We are not currently selling this medicine.